The popularity of Ozempic and Wegovy could change how companies operate.
HOUSTON — A new class of drugs called GLP-1, originally designed to fight type two diabetes, have exploded in popularity thanks to their ability to help people lose weight.
Sold under brand names like Ozempic and Wegovy, they slow the emptying of your stomach, making you feel fuller, resulting in you eating less. they have already noticed changes in buying patterns in customers taking the drugs. It’s probably not surprising, but they are buying less food. In the wake of that report, companies like Hershey and Pepsi saw their stocks slide. analysts took things even further.
Other investors see a chance to make money. According to analysts at one investment bank, these drugs could help airlines save money. If you assume the average passenger lost ten pounds, it would reduce weight on a single flight by 1,790 pounds. That would save an airline about 80 million dollars a year in fuel costs. Some real food for thought.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
How Ozempic and Wegovy turned Novo Nordisk into a $400 billion companyHow Ozempic and Wegovy turned Novo Nordisk into a $400 billion company
Read more »
Ozempic and Wegovy aren’t affecting PepsiCo’s business much — but this trend isStock sold off last week after Walmart said Wegovy and Ozempic were leading customers to buy fewer groceries and cut back on calories
Read more »
Should Walmart be data-mining your Ozempic prescriptions?Walmart says it’s using customer data to see if people who fill Wegovy or Ozempic prescriptions are buying less food, raising privacy questions.
Read more »
Novo Nordisk stops Ozempic kidney trial after early signs of successNovo Nordisk (NOVOb.CO) said on Tuesday it will stop a trial studying Ozempic to treat kidney failure in diabetes patients ahead of schedule because it was clear from an interim analysis that the treatment would succeed.
Read more »
Dialysis company shares plunge after Ozempic trial success vs. kidney troubleSteven Goldstein is based in London and responsible for MarketWatch's coverage of financial markets in Europe, with a particular focus on global macro and commodities. Previously, he was Washington bureau chief, directing MarketWatch's economic, political and regulatory coverage. Follow Steve on Twitter: MKTWgoldstein.
Read more »